Application of miR-92b as target in development of renal fibrosis drugs or preparation of renal fibrosis animal models

The TGF-β/SMAD3 signaling pathway is regulated by knockout or overexpression of miR-92b, and the problem of low efficiency in the treatment of renal fibrosis in the prior art is solved, effective regulation of renal fibrosis is achieved, and new treatment strategies are provided .

CN119055673APending Publication Date: 2024-12-03SHENZHEN PEOPLES HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411208640.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-08
Filing Date
2024-08-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing methods for treating renal fibrosis are inefficient and have insufficient understanding of renal fibrosis cell and molecular mechanisms, resulting in a lack of effective strategies for treatment strategies.

Method used

Using miR-92b as a target, renal fibrosis drugs are developed or animal models of renal fibrosis are prepared, and the TGF-β/SMAD3 signaling pathway is regulated through knockout or overexpression of miR-92b to inhibit the renal fibrosis process.

Benefits of technology

By aggravating or overexpressing miR-92b knockout, miR-92b directly targets TGF-β receptor 1, improving renal fibrosis by inhibiting TGF-β/SMAD3 signaling pathway, providing new treatment and prevent renal fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005019745880000011
    Figure HDA0005019745880000011
  • Figure HDA0005019745880000012
    Figure HDA0005019745880000012
  • Figure HDA0005019745880000021
    Figure HDA0005019745880000021
Patent Text Reader

Abstract

The invention discloses an application of miR-92b as a target in development of a renal fibrosis drug or preparation of a renal fibrosis animal model. The invention provides an application of a miR-92b related biological material. The application is characterized in that the application is an application in preparation of a renal fibrosis medicine. The miR-92b related biological material can be miR-92b, a precursor RNA (Ribonucleic Acid) of the miR-92b, a miR-92b analogue or a specific DNA (Deoxyribose Nucleic Acid) molecule of the miR-92b or the precursor RNA of the miR-92b obtained by transcription. The miR-92b related biological material can be used for treating and / or preventing renal fibrosis, and the biological material taking miR-92b as an inhibition target can be used for preparing a renal fibrosis animal model.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to a Chinese patent application filed on September 8, 2023 (application number: 202311156780.4), the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present invention belongs to the field of biomedicine and relates to the application of miR-92b as a target in the development of renal fibrosis drugs or the preparation of renal fibrosis animal models. Specifically, it relates to the application of miR-92b as a promoting target in the development of renal fibrosis drugs or the application of miR-92b as an inhibiting target in the preparation of renal fibrosis animal models. Background Art

[0004] Renal fibrosis is a common pathological feature of nearly all progressive chronic kidney diseases (CKD), including diabetic nephropathy (DKD) and obstructive nephropathy, a process that greatly impairs the renal regenerative potential, leading to long-term functional decline. Currently, there are no approved effective treatments for renal fibrosis. Therefore, improving the understanding of the cellular and molecular mechanisms of renal fibrosis is crucial, not only to gain new insights into the pathogenesis of this process, but also to develop rational strategies for the treatment of patients with fibrotic kidney disease.

[0005] During renal fibrosis, transforming growth factor-β (TGF-β) plays a key role in chronic inflammatory changes in the interstitium and accumulation of extracellular matrix (ECM). TGF-β1 can induce renal fibrosis by activating canonical (Smad-based) and non-canonical (non-Smad-based) signaling pathways, leading to myofibroblast activation, excessive ECM production, and inhibition of ECM degradation. The activated SMAD complex enters the nucleus and transcribes fibrosis-related proteins such as type I collagen (COL1A1) and smooth muscle actin (SMA). During fibrosis, SMAD3 requires phosphorylation to achieve nuclear translocation and transcriptional regulation of target genes.

[0006] MicroRNAs (miRNAs) are the most studied class of small non-coding RNAs.

[0007] The key microRNAs that regulate the activity of the TGF-B1 signaling pathway have not yet been elucidated. Summary of the invention

[0008] The purpose of the present invention is to provide the use of miR-92b as a target in developing renal fibrosis drugs or preparing renal fibrosis animal models.

[0009] The present invention provides an application of miR-92b related biomaterials, characterized in that the application is an application in the preparation of renal fibrosis drugs.

[0010] Exemplarily, the miR-92b-related biological material may be miR-92b (a type of miRNA).

[0011] Exemplarily, the miR-92b-related biological material may be a precursor RNA of miR-92b.

[0012] Exemplarily, the miR-92b-related biological material may be a miR92b analog.

[0013] Exemplarily, the miR-92b-related biological material may be a specific DNA molecule; the specific DNA molecule is transcribed to obtain miR-92b.

[0014] Exemplarily, the miR-92b-related biological material may be a specific DNA molecule; the specific DNA molecule is transcribed to obtain the precursor RNA of miR-92b.

[0015] Exemplarily, the miR-92b-related biological material may be a specific DNA molecule; the RNA transcribed from the specific DNA molecule contains miR-92b.

[0016] Exemplarily, the miR-92b-related biological material may be a specific DNA molecule; the specific DNA molecule is transcribed to obtain a precursor RNA containing miR-92b in RNA.

[0017] Exemplarily, the miR-92b-related biological material may be a recombinant plasmid or a recombinant virus.

[0018] Exemplarily, the recombinant plasmid may be a recombinant plasmid having any of the above-mentioned specific DNA molecules.

[0019] Exemplarily, the recombinant virus may be a recombinant virus having any of the specific DNA molecules described above.

[0020] Exemplarily, the recombinant virus may be a recombinant adeno-associated virus.

[0021] Exemplarily, the recombinant virus may be a recombinant AVV9 virus.

[0022] miR-92b is shown as SEQ ID NO: 1 (single-stranded RNA molecule).

[0023] The precursor RNA of miR-92b is shown in SEQ ID NO: 2 (single-stranded RNA molecule).

[0024] The miR92b analog (miR92b mimic) is a double-stranded RNA molecule, one strand of which is shown as SEQ ID NO:5, and the other strand of which is shown as SEQ ID NO:6.

[0025] Illustratively, the specific DNA molecule is shown as SEQ ID NO:4.

[0026] The present invention also protects an application, characterized in that: the application is the application of a biomaterial taking miR-92b as an inhibition target in the preparation of an animal model of renal fibrosis.

[0027] The present invention also protects an application, characterized in that: the application is the application of a biological material using the miR-92b encoding gene in the animal genome as a knockout target in the preparation of an animal model of renal fibrosis.

[0028] Exemplarily, the biological material with the miR-92b encoding gene in the animal genome as the knockout target can be the biological material knocked out using the crispr / cas9 technology.

[0029] Exemplarily, the biological material with the miR-92b encoding gene in the animal genome as the knockout target can be a biological material that is knocked out using the CRISPR / Cas9 dual target.

[0030] The knockout target is specifically shown in SEQ ID NO:3.

[0031] The biomaterial with miR-92b as the inhibition target may specifically be a miR-92b inhibitor.

[0032] Exemplarily, the miR-92b inhibitor is a single-stranded RNA molecule shown in SEQ ID NO:7.

[0033] The present invention has verified the following contents by experiment: miR-92b knockout aggravates the renal fibrosis of UUO model mice and uIRI model mice; Overexpression of miR-92b inhibits the renal fibrosis of UUO model mice. Therefore, the relevant biomaterials of miR-92b can be used for the treatment and / or prevention of renal fibrosis, and the biomaterials with miR-92b as the inhibition target can be used for the preparation of renal fibrosis animal model (compared with UUO model and uIRI model in the prior art, the model has more serious renal fibrosis symptoms). On the basis of finding the relevant functions of miR-92b to renal fibrosis, the inventor further confirmed that miR-92b directly targets TGF-β receptor 1 (TGFBR1) by bioinformatics analysis, RNA sequencing analysis, luciferase reporter gene assay, qPCR analysis and western blotting and other experimental methods, so as to improve renal fibrosis by inhibiting TGF-β / SMAD3 signaling pathway. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1The results of Masson staining and Sirius red staining in step 2 of Example 1 are shown.

[0035] Figure 2 This is the result of the relative expression level of the target gene in step 2 of Example 1.

[0036] Figure 3 The results of Western Blot detection of target proteins (COL1A1, COL3A1, CTGF) in step 2 of Example 1.

[0037] Figure 4 The results of immunofluorescence staining and immunohistochemistry in step 2 of Example 1 are shown.

[0038] Figure 5 The results of Western Blot detection of target proteins (E-cadherin, α-SMA) in step 2 of Example 1.

[0039] Figure 6 The results of Masson staining and Sirius red staining in step 3 of Example 1 are shown.

[0040] Figure 7 The results of immunofluorescence staining and immunohistochemistry in step 3 of Example 1 are shown.

[0041] Figure 8 This is the result of Western Blot detection of the target protein in step 3 of Example 1.

[0042] Fig. 9 This is the result of the relative expression level of the target gene in step 3 of Example 1.

[0043] Fig.10 The results of Masson staining and Sirius red staining in step 4 of Example 1 are shown.

[0044] Fig.11 The results of immunofluorescence staining and immunohistochemistry in step 4 of Example 1 are shown.

[0045] Fig.12 This is the result of Western Blot detection of the target protein in step 4 of Example 1.

[0046] Fig.13 This is the result of the relative expression level of the target gene in step 4 of Example 1.

[0047] Fig.14 The results of Western Blot detection of target proteins (p-SMAD3, SMAD3, COL1A1, α-SMA) in step 1 of Example 2.

[0048] Fig.15 This is the result of the relative expression level of the target gene in step 1 of Example 2.

[0049] Fig.16 This is the result of Western Blot detection of target proteins (SMAD3 and H3) in step 1 of Example 2.

[0050] Fig.17 The results of Western Blot detection of target proteins (p-SMAD3, SMAD3, COL1A1, α-SMA) in step 2 of Example 2.

[0051] Fig.18 This is the result of the relative expression level of the target gene in step 2 of Example 2.

[0052] Fig.19 This is the result of Western Blot detection of target proteins (SMAD3 and H3) in step 2 of Example 2.

[0053] Fig. 20 In Example 3, the four groups of mice in step 2 of Example 1 were used as the subjects, and the results of Western Blot detection of TGFBR1 and β-actin and the results of quantitative PCR detection of TGFBR1 gene were obtained.

[0054] Fig.21 In Example 3, the three groups of mice in step 4 of Example 1 were used as the subjects, and the results of Western Blot detection of TGFBR1 and β-actin and the results of quantitative PCR detection of TGFBR1 gene were obtained.

[0055] Fig. 22 These are the results of Masson staining and Sirius red staining in Example 4.

[0056] Fig.23 These are the results of immunofluorescence staining and immunohistochemistry in Example 4.

[0057] Fig.24 This is the result of Western Blot detection of the target protein in Example 4.

[0058] Fig.25 This is the result of the relative expression level of the target gene in Example 4. DETAILED DESCRIPTION

[0059] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0060] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0061] Each independent experiment was repeated three times. SPSS software (version 22.0) was used to make the raw data conform to normal distribution and the 1-sample KS analysis was performed using nonparametric tests. Values ​​are expressed as mean ± SD. Two-tailed unpaired Student's t test was used to compare the two groups. For comparisons of more than two groups, one-way analysis of variance (ANOVA) and Bonferroni post hoc test were used. Correlation coefficients were calculated using Spearman correlation test. To avoid bias, all statistical analyses were performed in a blinded manner. *p<0.05, **p<0.01, ***p<0.001 were considered statistically significant.

[0062] The mature miRNA of MiR-92b is shown as SEQ ID NO:1.

[0063] The miR-92b precursor RNA is shown as SEQ ID NO:2.

[0064] M92KO mice: C57BL / 6J mice were used as the starting mice, and CRISPR / Cas9 dual targets were used for targeted knockout to obtain homozygous knockout mice, namely M92KO mice. Compared with C57BL / 6J mice, the difference between M92KO mice is only that the segment shown in SEQ ID NO: 3 is missing in the genomic DNA (homozygous means that a pair of homologous chromosomes have the same deletion).

[0065] All mouse care and use procedures were in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All mouse experiments were approved by the Ethics Committee of Shenzhen People's Hospital, Second Clinical Medical College of Jinan University (Shenzhen, China).

[0066] HK2 cells: human proximal tubule epithelial cells. HK2 cells were cultured in MEM medium containing 10% bovine serum, 100 U / mL penicillin, 100 mg / mL streptomycin, and NEAA (NEAA refers to non-essential amino acids, i.e., L-alanine, L-glutamic acid, L-asparagine, L-aspartic acid, L-proline, L-serine, and glycine). HK2 cell culture conditions: 37°C, 5% CO2.

[0067] miR92b analog (miR92b mimic) is a double-stranded RNA molecule;

[0068] One strand is (SEQ ID NO: 5): 5′-uauugcacucgucccggccucc-3′;

[0069] The other strand is (SEQ ID NO: 6): 5'-AGGCCGGGACGAGUGCAAUAUU-3'.

[0070] The mimic control is a double-stranded RNA molecule;

[0071] One strand is: 5′-UUCUCCGAACGUGUCACGUTT-3′;

[0072] The other strand is: 5'-acgugacacguucggagaat-3'.

[0073] The miR-92b inhibitor (miR-92bi) is a single-stranded RNA molecule;

[0074] The sequence is (SEQ ID NO: 7): 5'-GGAGGCCGGGACGAGUGCAAUA-3'.

[0075] The inhibitor control was a single-stranded RNA molecule;

[0076] The sequence is: 5'-CAGUACUUUUUGUGUAGUACAA-3'.

[0077] In the examples, RNA molecules were transiently transfected using Lipofectamine 3000.

[0078] The primers for PCR detection of each gene are as follows:

[0079] Detection of β-actin gene: GGCTGTATTCCCCTCCATCG; CCAGTTGGTAACAATGCCATGT.

[0080] Detection of Tgf-β1 gene: CTCCCGTGGCTTCTAGTGC; GCCTTAGTTGGACAGGATCTG.

[0081] Detection of Fn1 gene: ATGTGGACCCCTCCTGATAGT; GCCCAGTGATTTCAGCAAAGG.

[0082] Detection of Col1a1 gene: GCTCCTCTTAGGGGCCACT;CCACGTCTCACCATTGGGG.

[0083] Detection of Col3a1 gene: CTGTAACATGGAAACTGGGGAAA; CCATAGCTGAACTGAAAACCACC.

[0084] Detection of Col1a2 gene: GTAACTTCGTGCCTAGCAACA; CCTTTGTCAGAATACTGAGCAGC.

[0085] Detection of Ctgf gene: GGGCCTCTTCTGCGATTTC; ATCCAGGCAAGTGCATTGGTA.

[0086] The corresponding primary antibodies for the target proteins detected by Western Blot were: β-actin antibody (Abcam, Cat#ab8226), CTGF antibody (Abcam, Cat#ab6992), COL1A1 antibody (Novus, Cat#sc-293182), COL3A1 antibody (Novus, Cat#sc-514601), α-SMA antibody (Abcam, Cat#ab7817), and E-cadherin antibody (Wuhan Mitsubishi Pharmaceutical, Cat#20874-1-AP).

[0087] Example 1: Effects of knockout and overexpression of miR-92b on renal fibrosis

[0088] 1. Discovery of the correlation between MiR-92b and renal fibrosis

[0089] Wild-type mice and model mice (model mice were wild-type mice subjected to UUO-induced renal fibrosis) were used as research objects to compare the abundance of miRNA in renal tissue. The results showed that compared with wild-type mice, the expression level of miR-92b in the kidneys of model mice was significantly downregulated.

[0090] The renal tissues of non-CKD patients and CKD patients who underwent renal biopsy were used as the research objects to compare the abundance of miRNA. The results showed that the expression level of miR-92b in the renal tissues of CKD patients was significantly downregulated compared with that in the renal tissues of non-CKD patients.

[0091] MiR-92b knockout aggravates renal fibrosis in the UUO model (i.e., unilateral ureteral obstruction model)

[0092] WT model group: 8-week-old male C57BL / 6J mice were anesthetized by intraperitoneal injection of 2% sodium pentobarbital solution (4 ml / kg body weight); after anesthesia, the mice were placed prone on the experimental table and one side of the ureter was exposed. The ureter was ligated at two points near the renal hilum and the ureter was cut in the middle, and then the wound was sutured; after suture, the mice were placed in a standard cage for recovery.

[0093] M92KO model group: 8-week-old male M92KO mice were used, and the other parameters were the same as those of the WT model group.

[0094] WT sham operation group: the ureter was not ligated or cut off, and the rest was the same as the WT model group.

[0095] M92KO sham operation group: no ureteral ligation or cutting, and other M92KO model groups.

[0096] On the 7th day after surgery, the mice were killed.

[0097] After killing the mice, kidney tissue was obtained, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and stained with Masson and Sirius red, respectively. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of fibrosis area (%). The photos of Masson staining are shown in Figure 1 A, quantitative results see Figure 1 C (N = 6). Sirius red staining photos are shown in Figure 1 B, quantitative results are shown in Figure 1 D(N=6).

[0098] After killing the mice, kidney tissues were taken, total RNA was extracted, and cDNA was obtained after reverse transcription. Using cDNA as a template, quantitative PCR was used to detect the target gene, and normalization was performed based on β-actin mRNA expression. ΔΔ ct algorithm to obtain the relative expression of the target genes. The target genes are: Tgf-β1 gene (encoding fibrosis factor TGF-β1), Fn1 gene (encoding fibrosis factor Fn1), Col1a1 gene (encoding fibrosis factor COL1A1), Col3a1 gene (encoding fibrosis factor COL3A1). The results are shown in Figure 2 (N=6).

[0099] After killing the mice, kidney tissue was taken and lysed in a lysis buffer containing protease inhibitors and protein phosphatase inhibitors to extract total protein. The total protein extract was mixed with the loading buffer, boiled at 95°C for 5 minutes, and then subjected to gel electrophoresis using 12% SDS-PAGE. The gel was then transferred to a PVDF membrane, blocked with skim milk, and then subjected to Western Blot. The target proteins detected by Western Blot were: COL1A1, COL3A1, CTGF, and β-actin (internal reference). Photos of Western Blot are shown in Figure 3 A, quantitative results of COL1A1 reference β-actin are shown in Figure 3B (N = 6), the quantitative results of COL3A1 reference β-actin are shown in Figure 3 C (N = 6), the quantitative results of CTGF reference β-actin are shown in Figure 3 D(N=6).

[0100] After killing the mice, kidney tissue was taken, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken, and E-cadherin was detected by immunofluorescence staining, and α-SMA was detected by immunohistochemistry. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of positive area (%). Immunofluorescence staining method: paraffin sections were taken, incubated with primary antibody working solution at 4°C overnight, and then incubated with secondary antibody working solution at room temperature for 1 hour. In immunofluorescence staining: the primary antibody working solution was obtained by diluting E-cadherin antibody (Wuhan Sanying Biotechnology, Cat#20874-1-AP; RRID: AB_10697811) with PBS buffer to 100 times the volume, and the secondary antibody working solution was obtained by diluting Alexa Fluor 488-labeled secondary antibody (invitrogen, Cat#A-11008; RRID: AB_143165) with PBS buffer to 400 times the volume. Immunohistochemistry method: paraffin sections were taken, dewaxed and antigen repaired, and then incubated with primary antibody working solution at 4°C overnight, then incubated with secondary antibody working solution at room temperature for 20 minutes, then incubated with streptavidin-horseradish peroxidase for 30 minutes, then developed with DAB substrate, then stained with hematoxylin, and then sealed with neutral resin. In immunohistochemistry: the primary antibody working solution was obtained by diluting α-SMA antibody (Wuhan Sanying Biotechnology, Cat#14395-1-AP; RRID:AB_2223009) to 100 times the volume with PBS buffer, and the secondary antibody working solution was a ready-to-use biotinylated secondary antibody (Zhongshan Jinqiao, Cat#PV9001). For photos of immunofluorescence staining for E-cadherin, see Figure 4 A, Immunohistochemical detection of α-SMA. Figure 4 B, quantitative results are shown in Figure 4 C(N=6).

[0101] After killing the mice, kidney tissue was taken and lysed in a lysis buffer containing a mixture of protease inhibitors and protein phosphatase inhibitors to extract total protein. The total protein extract was mixed with the loading buffer, boiled at 95°C for 5 minutes, and then subjected to gel electrophoresis using 12% SDS-PAGE. The gel was then transferred to a PVDF membrane, blocked with skim milk, and then subjected to Western Blot. The target proteins detected by Western Blot were: E-cadherin, α-SMA, and β-actin (internal reference). Photos of Western Blot are shown in Figure 5 A, the relative abundance of α-SMA and E-cadherin after normalization with β-actin is shown in Figure 5 B(N=6).

[0102] according to Figure 1 It can be seen that compared with the WT sham operation group, the renal sections of the WT model group mice showed obvious renal fibrosis; compared with the WT model group, the renal sections of the M92KO model group mice showed more obvious renal fibrosis. Figure 2 It can be seen that compared with the WT sham operation group, the expression of fibrosis factors in the kidneys of mice in the WT model group was significantly upregulated; compared with the WT model group, the expression of fibrosis factors in the kidneys of mice in the M92KO model group was further significantly upregulated. Figure 3 , Figure 4 and Figure 5 It can be seen that compared with the WT sham operation group, the levels of COL1A1, COL3A1 and CTGF in the kidneys of the WT model group mice were increased, the level of E-cadherin was decreased, and the level of α-SMA was increased; compared with the WT model group, the levels of COL1A1, COL3A1 and CTGF in the kidneys of the M92KO model group mice were further increased, the level of E-cadherin was further decreased, and the level of α-SMA was further increased. The results showed that the loss of miR-92b increased the degree of renal fibrosis in the UUO model.

[0103] MiR-92b knockout aggravates renal fibrosis in the uIRI model (i.e., unilateral ischemia-reperfusion injury model)

[0104] Model group: 8-week-old male C57BL / 6J mice were anesthetized by intraperitoneal injection of 2% sodium pentobarbital solution (4 ml / kg body weight); after anesthesia, the mice were placed on a heating pad (body temperature maintained at 37°C), laparotomy and one side of the renal pedicle was exposed, the renal artery was clamped with a mouse microartery clamp for 45 minutes, and then the mouse microartery clamp was removed to allow reperfusion of the kidney, and then the wound was sutured; after suturing, the mice were placed in a standard cage for recovery.

[0105] M92KO group: 8-week-old male M92KO mice were used, and the rest were the same as the model group.

[0106] Sham operation group: the renal artery was not clamped, and other conditions were the same as those of the model group.

[0107] 24 days after surgery, the mice were killed.

[0108] After killing the mice, kidney tissues were obtained, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and stained with Masson and Sirius red, respectively. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area. Photos of Masson staining are shown in Figure 6 A, quantitative results see Figure 6 C (N = 6). Sirius red staining photos are shown in Figure 6 B, quantitative results are shown in Figure 6 D(N=6).

[0109] After killing the mice, kidney tissue was taken, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and E-cadherin was detected by immunofluorescence staining, and α-SMA was detected by immunohistochemistry. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of positive area (%). The methods of immunofluorescence staining and immunohistochemistry are the same as step 2. Photos of immunofluorescence staining for E-cadherin are shown in Figure 7 A, quantitative results see Figure 7 C (N = 6). Photos of immunohistochemical detection of α-SMA are shown in Figure 7 B, quantitative results are shown in Figure 7 D(N=6).

[0110] After killing the mice, kidney tissue was taken and lysed in a lysis buffer containing a mixture of protease inhibitors and protein phosphatase inhibitors to extract total protein. The total protein extract was mixed with the loading buffer, boiled at 95°C for 5 minutes, and then subjected to gel electrophoresis using 12% SDS-PAGE. The gel was transferred to a PVDF membrane, blocked with skim milk, and then subjected to Western Blot. The target proteins detected by Western Blot were: COL1A1, COL3A1, α-SMA, and β-actin (internal reference). Photos of Western Blot are shown in Figure 8 A, quantitative results of COL1A1 reference β-actin are shown in Figure 8 B (N = 6), the quantitative results of COL3A1 reference β-actin are shown in Figure 8 C (N = 6), the quantitative results of α-SMA reference β-actin are shown in Figure 8 D(N=6).

[0111] After killing the mice, kidney tissues were taken, total RNA was extracted, and cDNA was obtained after reverse transcription. Using cDNA as a template, quantitative PCR was used to detect the target gene, and normalization was performed based on β-actin mRNA expression. ΔΔ ct algorithm to obtain the relative expression of the target gene. The target genes are: Col1a1 gene, Col1a2 gene (encoding COL1A2), Col3a1 gene, Fn1 gene or Ctgf gene (encoding CTGF). The results are shown in Fig. 9 (N=6).

[0112] according to Figure 6 It can be seen that compared with the sham operation group, the renal sections of the model group mice showed obvious renal fibrosis; compared with the model group, the renal sections of the M92KO group mice showed more obvious renal fibrosis. Figure 7 It can be seen that compared with the sham operation group, the E-cadherin level in the kidneys of the mice in the model group was reduced, and the α-SMA level was increased; compared with the model group, the E-cadherin level in the kidneys of the mice in the M92KO group was further reduced, and the α-SMA level was further increased. Figure 8 It can be seen that compared with the sham operation group, the levels of COL1A1, COL3A1 and α-SMA in the kidneys of the mice in the model group were increased; compared with the model group, the levels of COL1A1, COL3A1 and α-SMA in the kidneys of the mice in the M92KO group were further increased. Fig. 9 It can be seen that compared with the sham operation group, the expression of fibrosis factors in the kidneys of mice in the model group was significantly upregulated; compared with the model group, the expression of fibrosis factors in the kidneys of mice in the M92KO group was further significantly upregulated. The results showed that the loss of miR-92b increased the degree of renal fibrosis in the uIRI model.

[0113] 4. MiR-92b overexpression alleviates renal fibrosis in UUO model

[0114] M92OE group: 8-week-old male C57BL / 6J mice were injected with 200 μL AAV9-miR92b virus solution through the tail vein and then fed normally for 2 weeks; then, 2% sodium pentobarbital solution (4 ml / kg body weight) was injected intraperitoneally for anesthesia; after anesthesia, the mice were placed prone on the experimental table and one side of the ureter was exposed, and then the ureter was ligated at two points near the renal hilum and cut in the middle, and then the wound was sutured; after suturing, the mice were placed in a standard cage for recovery.

[0115] Ctrl group: AAV9-miR92b virus solution was replaced with an equal volume of AAV9 virus solution, and the rest was the same as the M92OE group.

[0116] Sham operation group: No AAV9-miR92b virus solution was injected and the ureter was not ligated or cut off. Other conditions were the same as those of the M92OE group.

[0117] The AAV9-miR92b virus solution was obtained by suspending the AAV9-miR92b virus in a 0.15 mol / L NaCl aqueous solution. The virus concentration was 1×10 12 vg / mL. AAV9 virus solution was obtained by suspending AAV9 virus in 0.15 mol / L NaCl aqueous solution, with a virus concentration of 1×10 12 vg / mL. AAV9-miR92b virus (product of Shanghai GeneCare Gene Medical Technology Co., Ltd.): recombinant virus, using AAV9 virus as a vector to express the DNA molecule shown in SEQ ID NO: 4. AAV9 virus (product of Shanghai GeneCare Gene Medical Technology Co., Ltd.): control virus of AAV9-miR92b virus; the only difference between the genomic DNA of the AAV9-miR92b recombinant virus and that of the AAV9-miR92b recombinant virus is the lack of the DNA molecule shown in SEQ ID NO: 4.

[0118] Ten days after surgery, the mice were killed.

[0119] After killing the mice, kidney tissue was obtained, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and stained with Masson and Sirius red, respectively. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of fibrosis area (%). The photos of Masson staining are shown in Fig.10 A, quantitative results see Fig.10 C (N = 6). Sirius red staining photos are shown in Fig.10 B, quantitative results are shown in Fig.10 D(N=6).

[0120] After killing the mice, kidney tissue was taken, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and E-cadherin was detected by immunofluorescence staining, and α-SMA was detected by immunohistochemistry. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of positive area (%). The methods of immunofluorescence staining and immunohistochemistry are the same as step 2. Photos of immunofluorescence staining for E-cadherin are shown in Fig.11 A, quantitative results see Fig.11 C (N = 6). Photos of immunohistochemical detection of α-SMA are shown in Fig.11 B, quantitative results are shown in Fig.11 D(N=6).

[0121] After killing the mice, kidney tissue was taken and lysed in a lysis buffer containing a mixture of protease inhibitors and protein phosphatase inhibitors to extract total protein. The total protein extract was mixed with the loading buffer, boiled at 95°C for 5 minutes, and then subjected to gel electrophoresis using 12% SDS-PAGE. The gel was transferred to a PVDF membrane, blocked with skim milk, and then subjected to Western Blot. The target proteins detected by Western Blot were: COL1A1, COL3A1, α-SMA, and β-actin (internal reference). Photos of Western Blot are shown in Fig.12 A, quantitative results of COL1A1 reference β-actin are shown in Fig.12 B (N = 6), the quantitative results of COL3A1 reference β-actin are shown in Fig.12 C (N = 6), the quantitative results of α-SMA reference β-actin are shown in Fig.12 D(N=6).

[0122] After killing the mice, kidney tissues were taken, total RNA was extracted, and cDNA was obtained after reverse transcription. Using cDNA as a template, quantitative PCR was used to detect the target gene, and normalization was performed based on GAPDH mRNA expression. ΔΔ ct algorithm to obtain the relative expression of the target gene. The target gene is: Col1a1 gene, Col1a2 gene, Col3a1 gene, Fn1 gene or Ctgf gene. The results are shown in Fig.13 (N=6).

[0123] according to Fig.10 It can be seen that compared with the sham operation group, the renal sections of the Ctrl group mice showed obvious renal fibrosis; compared with the Ctrl group, the renal fibrosis degree of the M92OE group mice was reduced. Fig.11 It can be seen that compared with the sham operation group, the E-cadherin level in the kidneys of the Ctrl group mice was decreased, and the α-SMA level was increased; compared with the Ctrl group, the E-cadherin level in the kidneys of the M92OE group mice was increased, and the α-SMA level was decreased. Fig.12 It can be seen that compared with the sham operation group, the levels of COL1A1, COL3A1 and α-SMA in the kidneys of the Ctrl group mice were increased; compared with the Ctrl group, the levels of COL1A1, COL3A1 and α-SMA in the kidneys of the M92OE group mice were decreased. Fig.13 It can be seen that compared with the sham operation group, the expression of fibrosis factors in the kidneys of mice in the Ctrl group was significantly upregulated; compared with the Ctrl group, the expression of fibrosis factors in the kidneys of mice in the M92OE group was significantly downregulated. The results showed that the overexpression of miR-92b alleviated renal fibrosis in the UUO model.

[0124] Example 2: MiR-92b regulates activation of TGF-β signaling pathway

[0125] Eight-week-old male C57BL / 6 mice (WT mice) and eight-week-old male M92KO mice were used as research subjects for differential gene expression analysis. Compared with WT mice, 1181 genes were significantly upregulated and 950 genes were significantly downregulated in the kidneys of M92KO mice (P<0.05). IPA analysis showed that the "TGF-β signaling pathway" was the primary pathway affected by miR-92b knockout. TGF-β is considered to be the main cytokine / growth factor produced in injured or diseased tissues, where it activates fibroblasts and promotes ECM production. TGF-β binds to heterodimeric receptors composed of TGF-β type I and type II half receptors on the plasma membrane, and together induces phosphorylation of SMAD2 and SMAD3 transcription factors, mediating canonical signaling. Phosphorylated SMAD2 and SMAD3 interact with Smad4 in the cytoplasm, from where they are transported to the nucleus to induce gene transcription. Compared with WT mice, both TGFBR1 and TGFBR2 were upregulated in the kidneys of M92KO mice.

[0126] The TargetScan database was used to predict the downstream targets of miR-92b, and 1292 downstream conserved target genes in humans and mice were predicted. The IPA of the 1292 genes showed that "TGF-β receptor signaling" and "TGF-β receptor signaling in skeletal dysplasia" were the top signaling pathways predicted by TargetScan.

[0127] 1. Transfection experiment of miR92b mimic and its control

[0128] Group A: HK2 cells were transfected with mimic control (working concentration of 40nmol / L) and cultured for 24 hours. Group B: HK2 cells were transfected with miR92b mimic (working concentration of 40nmol / L) and cultured for 24 hours. Group C: HK2 cells were transfected with mimic control (working concentration of 40nmol / L) and TGF-β (working concentration of 2ng / mL) and cultured for 24 hours. Group D: HK2 cells were transfected with miR92b mimic (working concentration of 40nmol / L) and TGF-β (working concentration of 2ng / mL) and cultured for 24 hours.

[0129] Western blot was performed. The detection targets were: p-SMAD3, SMAD3, COL1A1, α-SMA and β-actin (internal reference). The results are shown in Fig.14(N=3). Under TGF-β stimulation, p-SMAD3 / SMAD3 increased, and COL1A1 and α-SMA were upregulated in HK2 cells. After miR92b mimic treatment, p-SMAD3 / SMAD3 decreased, and COL1A1 and α-SMA were downregulated in HK2 cells.

[0130] Quantitative PCR detected the following target genes: COL1A1 gene, E-cadherin gene and SERPINE1 gene. The results are shown in Fig.15 (From left to right, corresponding to COL1A1 gene, E-cadherin gene and SERPINE1 gene; N=5). Under TGF-β stimulation, COL1A1 gene and SERPINE1 gene expression were up-regulated, and E-cadherin gene expression was down-regulated. miR92b mimic treatment could prevent the changes caused by TGF-β stimulation.

[0131] Western blot was performed to detect SMAD3 and H3 in nuclear extracts. The results of SMAD3 abundance and H3 abundance are shown in Fig.16 Treatment with miR-92b mimics could inhibit nuclear SMAD3 localization induced by TGF-β stimulation.

[0132] II. Transfection experiment of miR-92bi and its control

[0133] Basically the same as step 1, the only difference is that miR-92bi is used instead of miR92b mimic, and the inhibitor control is used instead of the mimic control.

[0134] Results Figures 17 to 19 The miR-92b inhibitor (miR-92bi) increased TGF-β-mediated upregulation of SMAD3 phosphorylation, upregulation of COL1A1 and α-SMA protein levels, upregulation of COL1A1 and SERPINE1 mRNA levels, and nuclear accumulation of SMAD3.

[0135] Example 3: TGFBR1 is a direct target of miR-92b

[0136] Using StarBase (http: / / starbase.sysu.edu.cn / ), we found that TGFBR1 is a potential target of miR-92b in both humans and mice.

[0137] HK2 cells were transfected with miR92b mimic, and samples were taken at different times to determine the mRNA level of TGFBR1 using qPCR analysis. HK2 cells were transfected with miR92b mimic and / or mimic control at different doses, and the mRNA level of TGFBR1 was determined using qPCR analysis. miR92b mimic reduced the mRNA level of TGFBR1 in a time- and dose-dependent manner.

[0138] Two plasmids, TGFBR1 3′-UTR-WT and TGFBR1-3′-UTR-mt, were constructed. Each plasmid was transfected into HK2 cells with miR92b mimic and / or mimic control at different doses. Luciferase activity was detected. In cells transfected with TGFBR1-3′-UTR-WT, miR92b mimic reduced the activity of luciferase reporter protein in a dose-dependent manner. In cells transfected with TGFBR1-3′-UTR-MT, miR92b mimic had no effect on the activity of luciferase reporter protein. The results showed that TGFBR1 is a direct target mRNA of miR-92b.

[0139] HK2 cells were treated with miR92b mimic (or mimic control) with or without TGF-β. HK2 cells were treated with miR-92bi (or inhibitor control) with or without TGF-β. After treatment, the protein levels of TGFBR1 and β-actin in cells were detected by Western blot. Treatment with miR92b mimic inhibited the upregulation of TGFBR1 in HK2 cells induced by TGF-β, while treatment with miR-92bi enhanced the upregulation of TGFBR1 in HK2 cells induced by TGF-β.

[0140] HK2 cells were treated with miR-92bi (or inhibitor control) with or without siRNA TGFBR1. TGFBR1, p-SMAD3, SMAD3, p-SMAD2, SMAD2, and β-actin HK2 were detected by western blotting. In the presence of TGF-β, siRNA TGFBR1 treatment reduced the phosphorylation of SMAD3 in cells, and there was no further change after miR-92bi treatment. qPCR analysis of COLL1A1 and α-SMA mRNA expression levels showed that TGFBR1 knockdown inhibited TGF-β-induced α-SMA and COL1A1 mRNA levels, while α-SMA and COL1A1 mRNA levels did not change after miR-92bi treatment.

[0141] HK2 cells were treated with miR92b mimic (or mimic control) with or without Ad TGFBR1 (adenovirus overexpressing Tgfbr1). TGFBR1, p-SMAD3, SMAD3, and β-actin levels were detected by western blotting. COLL1A1 and α-SMA mRNA levels were detected by qPCR analysis. Ad TGFBR1 increased the phosphorylation of Smad3 and the mRNA levels of a-SMA and COL1A1 in HK2 cells stimulated by TGF-β, and these changes were not affected by treatment with miR-92b mimic.

[0142] The four groups of mice in step 2 of Example 1 were used as the subjects, and kidney tissues were obtained after being killed; total protein was extracted, and TGFBR1 and β-actin were detected by Western Blot. The quantitative results of TGFBR1 and β-actin are shown in Fig. 20 Left figure; total RNA was extracted and reverse transcribed to obtain cDNA, and cDNA was used as a template to detect the relative expression of TGFBR1 gene by quantitative PCR, see Fig. 20 The three groups of mice in step 4 of Example 1 were used as the subjects, and kidney tissues were obtained after being killed; total protein was extracted, and Western Blot was used to detect TGFBR1 and β-actin. The quantitative results of TGFBR1 and β-actin are shown in Fig.21 Left figure; total RNA was extracted and reverse transcribed to obtain cDNA, and cDNA was used as a template to detect the relative expression of TGFBR1 gene by quantitative PCR, see Fig.21 Right panel. Overexpression suppressed the upregulation of Tgfbr1 mRNA and protein levels in the kidneys of UUO mice, while knockout enhanced the upregulation of Tgfbr1 mRNA and protein levels in the kidneys of UUO mice.

[0143] In summary, miR-92b inhibits the expression of Tgfbr1 by directly binding to the 3′-UTR of Tgfbr1, thereby regulating the activation of the TGF-β signaling pathway.

[0144] Example 4. TGFBR1 deficiency inhibits renal injury induced by miR-92b knockout in UUO mice

[0145] Group A: WT mice were transfected with AAV-Ctrl and sacrificed 7 days after UUO surgery.

[0146] Group B: WT mice were transfected with AAV-shTgfbr1 and sacrificed 7 days after UUO surgery.

[0147] Group C: M92KO mice were transfected with AAV-shTgfbr1 and sacrificed 7 days after UUO surgery.

[0148] After killing the mice, kidney tissue was obtained, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and stained with Masson and Sirius red, respectively. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of fibrosis area (%). The quantitative results of Masson staining are shown in Fig. 22 The quantitative results of Sirius red staining are shown in the left figure (N=6). Fig. 22 Right figure (N=6).

[0149] After killing the mice, kidney tissue was obtained, fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. Paraffin sections were taken and E-cadherin was detected by immunofluorescence staining, and α-SMA was detected by immunohistochemistry. ImageJ software (NIH, http: / / rsbweb.nih.gov / ij / ) was used to quantify the stained area and obtain the percentage of positive area (%). The results of E-cadherin are shown in Fig.23 The results of α-SMA are shown in the left figure (N=6). Fig.23 Right figure (N=6).

[0150] After killing the mice, kidney tissue was taken and lysed in a lysis buffer containing protease inhibitors and protein phosphatase inhibitors to extract total protein. The total protein extract was mixed with the loading buffer, boiled at 95°C for 5 minutes, and then subjected to gel electrophoresis using 12% SDS-PAGE. The gel was then transferred to a PVDF membrane, blocked with skim milk, and then subjected to Western Blot. The target proteins detected by Western Blot were: β-actin (internal reference), COL1A1, COL3A1, and α-SMA. The quantitative results of the reference β-actin are shown in Fig.24 (N=6).

[0151] After killing the mice, kidney tissues were taken, total RNA was extracted, and cDNA was obtained after reverse transcription. Using cDNA as a template, quantitative PCR was used to detect the target gene, and normalization was performed based on GAPDH mRNA expression. ΔΔ The ct algorithm was used to obtain the relative expression of the target gene. The target gene is the gene encoding the target protein. The target proteins are: COL1A1, Col1a2, COL3A1, FN1, Ctgf. The results are shown in Fig.25 (N=6).

[0152] After transfection with AAV-shTgfbr1, there was no significant difference in collagen deposition and profibrotic gene expression in the kidneys of miR-92b knockout UUO and WT UUO mice. The results indicate that TGFBR1 is an important target of miR-92b in renal fibrosis.

[0153] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. An application, characterized in that: The application is the application of miR-92b in the preparation of renal fibrosis drugs; miR-92b is shown in SEQ ID NO:

1.

2. An application, characterized in that: The application is the application of the precursor RNA of miR-92b in the preparation of a drug for renal fibrosis; the precursor RNA of miR-92b is shown in SEQ ID NO:

2.

3. An application, characterized in that: The application is the application of miR92b analogs in the preparation of renal fibrosis drugs; the miR92b analogs are double-stranded RNA molecules, one strand is as shown in SEQ ID NO: 5, and the other strand is as shown in SEQ ID NO:

6.

4. An application, characterized in that: The application is the application of the specific DNA molecule in the preparation of a drug for renal fibrosis; the specific DNA molecule is transcribed to obtain miR-92b; miR-92b is shown in SEQ ID NO:

1.

5. An application, characterized in that: The application is the application of the specific DNA molecule in the preparation of a drug for renal fibrosis; the specific DNA molecule is transcribed to obtain the precursor RNA of miR-92b; the precursor RNA of miR-92b is shown in SEQ ID NO:

2.

6. An application, characterized in that: The application is the application of the specific DNA molecule in the preparation of a drug for renal fibrosis; the RNA transcribed from the specific DNA molecule contains miR-92b; miR-92b is shown in SEQ ID NO:

1.

7. An application, characterized in that: The application is the application of the specific DNA molecule in the preparation of a drug for renal fibrosis; the specific DNA molecule is transcribed to obtain a precursor RNA containing miR-92b in RNA; the precursor RNA of miR-92b is shown in SEQ ID NO:

2.

8. An application, characterized in that: The application is the application of a recombinant plasmid or a recombinant virus in the preparation of a drug for renal fibrosis; the recombinant plasmid contains the specific DNA molecule described in any one of claims 4 to 7; the recombinant virus contains the specific DNA molecule described in any one of claims 4 to 7.

9. An application, characterized in that: The application is the use of a biomaterial using miR-92b as an inhibition target in the preparation of an animal model of renal fibrosis.

10. An application, characterized in that: The application is the use of a biological material with the miR-92b encoding gene in the animal genome as a knockout target in the preparation of an animal model of renal fibrosis.

Citation Information

Patent Citations

  • Application of miR-92b or inhibitor thereof in regulation and control of athletic ability or fatigue resistance

    CN116327948A

  • Non-coding RNA mediated neurological disease treatment

    CN116333994A